# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review with MRI of the brain and spine, seen the same day by multiple sclerosis neurology. **S**

## History of present illness

Ms. Jordan returns two weeks after her first visit, after MRI of the brain and spine this morning, and is seen by Dr. Watanabe of multiple sclerosis neurology on the same day. Her walking is unchanged: she uses her cane on campus and rests after about 100 meters. She has had no new symptoms and no symptom that came on over days. Her legs are stiff in the mornings. She still gets up twice a night to pass urine and sometimes has to hurry. She has started vitamin D3. The records of her original evaluation have not arrived. She asked about treatments that might slow the disease and how often she would need to be away from work for them. **S**

| Element | Detail |
|---|---|
| Walking | Cane on campus; rests after about 100 meters; unchanged |
| New symptoms | None |
| Bladder | Urgency; up twice a night |
| Imaging | MRI of the brain and cervical and thoracic spine with gadolinium this morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by mid-afternoon; no fever |
| Eyes | Negative | No blurred or double vision |
| Genitourinary | Positive | Urgency and nocturia twice; no burning |
| Musculoskeletal | Positive | Leg stiffness in the mornings |
| Neurological | Positive | Slowly worsening walking; no new numbness or weakness |
| Psychiatric | Negative | Mood steady |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**
- Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated **S**
- Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 84.2 kg; BMI 28.1 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 74 |
| Neurological | Spastic paraparetic gait with a cane in the right hand; hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs; brisk leg reflexes with extensor plantar responses; reduced vibration sense at the toes; EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Eyes | Visual acuity 20/20 in each eye; no relative afferent pupillary defect |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Active primary progressive multiple sclerosis** (G35.B1). MRI brain: fourteen T2 lesions, periventricular, juxtacortical and infratentorial (pons and left middle cerebellar peduncle), one enhancing right periventricular lesion. MRI spine: three cord lesions at C3, C5 and T6, each less than two segments long, with no compression. With more than a year of gradually worsening walking and no relapses, these meet the 2017 McDonald criteria for primary progressive multiple sclerosis (brain lesions in characteristic regions and two or more cord lesions), and the enhancing lesion makes it active. B12, TSH and HIV results exclude the main mimics. Dr. Watanabe advises ocrelizumab. Screening before therapy: hepatitis B surface antigen, core antibody and surface antibody all negative (not infected, not immune); immunoglobulins, liver tests and blood count normal; varicella IgG and measles, mumps and rubella IgG positive; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14, negative. **S**
   - Vaccines today: PCV20, recombinant zoster dose 1, Tdap and hepatitis B dose 1; second zoster and hepatitis B doses in about five weeks.
   - First ocrelizumab half-dose at least two weeks after the last vaccine.
   - Reproductive plans discussed privately with Dr. Watanabe and recorded in the confidential part of the chart.
2. **Spastic gait and fall risk** (R26.89). Spasticity limits her walking and stiffens her mornings; no falls. **S**
   - Start baclofen 5 mg three times a day, increasing to 10 mg three times a day once tolerated.
   - Physical therapy evaluation requested at intake; awaiting a first appointment.
3. **Neurogenic bladder** (N31.9). Urgency with a low post-void residual of 40 mL at intake, so a bladder-relaxing medicine is safe. **S**
   - Start mirabegron 25 mg daily rather than an anticholinergic, to avoid effects on concentration; blood pressure at each visit.
   - Continue timed voiding and fluids earlier in the day.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No new symptoms; relapse and pseudo-relapse plan explained with a written card |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Completed today | Diagnostic MRI with gadolinium: fourteen T2 lesions in characteristic regions; one enhancing lesion |
| Imaging | Spinal cord MRI | At diagnosis; later only for new spinal symptoms or diagnostic doubt | Completed today | Three cord lesions; no compression |
| Laboratory | Hepatitis B surface antigen, core antibody and surface antibody | Before the first dose | Up to date | All negative at intake: not infected, not immune; vaccination started today |
| Laboratory | Quantitative immunoglobulins | Before the first dose, then before each dose | Up to date | IgG 1080, IgM 110, IgA 210 mg/dL at intake |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Up to date | White cells 6.4, lymphocytes 1.9 at intake |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Up to date | Normal at intake |
| Laboratory | Varicella and measles immunity, tuberculosis blood test, HIV, hepatitis C, JC virus antibody | Before the first dose | Up to date | Varicella and measles immune; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14 |
| Medication safety | Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2) | Inactivated at least 2 weeks and live at least 4 weeks before the first dose | Completed today | PCV20, zoster dose 1, Tdap and hepatitis B dose 1 today; no live vaccine needed |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 2 in both legs; baclofen started |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Urgency and nocturia twice; post-void residual 40 mL at intake; mirabegron started; blood pressure 122/76 |
| Referral | Falls, walking aids and physical therapy | Every visit | Ordered | No falls; physical therapy evaluation requested at intake, first appointment awaited |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Tires by mid-afternoon; pacing and cooling advice given |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Up to date | 17 ng/mL at intake; vitamin D3 started at intake |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Up to date | PHQ-9 6 at intake, mostly fatigue and sleep items |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Letter describing her functional needs, without the diagnosis, given to her to send as she chooses |
| Referral | Multiple sclerosis neurology review | At diagnosis, then every 6 months on therapy | Completed today | Seen by Dr. Watanabe today |

## Goal progress

- Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks. In progress; target 2026-06-29. **S**
- No falls through eight months. In progress; target 2026-10-26. **S**
- 25-hydroxyvitamin D at least 30 ng/mL within four months. In progress; target 2026-06-29. **S**
- Up no more than once a night to pass urine within three months. In progress; target 2026-06-29. **S**
- Keep her full teaching and speaking schedule with the accommodations she chooses. In progress; target 2026-10-26. **S**
- No new or enlarging T2 lesions on the re-baseline MRI. In progress; target 2026-10-26. **S**

## Medication changes

- Started: Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated **S**
- Started: Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017), International Panel on Diagnosis of Multiple Sclerosis (Lancet Neurology)
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021), MAGNIMS, CMSC and NAIMS (Lancet Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Accommodation and Compliance: Multiple Sclerosis (2026), Job Accommodation Network (U.S. Department of Labor)
- Introduction to the Americans with Disabilities Act (2026), U.S. Department of Justice
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in five weeks for the second vaccine doses and baclofen titration; first ocrelizumab infusion to be booked at least two weeks after that visit. Same-day call for new or worsening symptoms lasting more than 24 hours. **S**
- Next scheduled visit 2026-04-20: five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion. **S**
